4147.TWO

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$650M	+6.5%	$-0.77	$-0.77–$-0.77	—	1
2027	$650M	+0.0%	$-1.07	$-1.07–$-1.07	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.23	$-0.27	-17.4%
2026-05-07	$-0.23	$0.06	+126.1%
2026-03-03	$-0.28	$-0.25	+10.7%
2025-11-05	$-0.29	$-0.05	+82.8%
2025-08-07	$-0.24	$-0.22	+9.6%
2025-05-08	$-0.15	$-0.12	+18.2%
2025-03-05	$-0.17	$-0.44	-158.8%
2024-11-08	$-0.17	$-0.14	+17.6%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
4147.TWOTaiMed Biologics Inc.	$60.90	+2.18%	$16.5B	—
4105.TWOTTY Biopharm Company Limited	$78.20	-0.13%	$19.4B	—
4728.TWOSunmax Biotechnology Co., Ltd.	$391.00	-1.01%	$21.3B	—
6541.TWTanvex BioPharma, Inc.	$30.70	+1.32%	$8.1B	—
6547.TWOMedigen Vaccine Biologics Corp.

TaiMed Biologics Inc.

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.

www.taimedbiologics.com

Employees: 799
IPO / List date: Jun 20, 2012
HQ: TW

Held by traders on TradeandTell

No one on the platform currently holds 4147.TWO.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 4147.TWO as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 4147.TWO yet.